HIV & AIDS Health Center
FDA: Don't Take Amevive With HIV
Nov. 18, 2005 -- The FDA and Biogen Idec are warning HIV-positive people not to take the psoriasis drug Amevive.
"Amevive should not be administered to patients infected with HIV," states a letter to doctors from Biogen, which makes Amevive.
The reason is that Amevive lowers counts of CD4+ T-lymphocytes, a type of white blood cell that's part of the body's immune system.
In HIV-positive people, lower CD4+ T-lymphocyte counts "might accelerate disease progression or increase complications of disease," states Biogen's letter.
Amevive is a biologic drug used to treat adults with moderate to severe chronic plaque psoriasis who are candidates for phototherapy (light therapy) or systemic therapy (which affects the whole body).
is common and often chronic (long lasting). It usually causes patches (called plaques) of itchy, scaly, and sometimes inflamed skin.
Possible side effects from Amevive should be reported to the FDA's MedWatch program (online at www.fda.gov/medwatch or by phone at (800) FDA-1088 or (800) 332-1088) or to Biogen ((866) 263-8483).
Most Popular Stories
- 6 Sex Mistakes Women Make
- 6 Sex Mistakes Men Make
- Pictures of Bugs and Their Bite Marks
- 10 Surprising Health Benefits of Sex
- Most Fattening Foods of Summer
- 15 Foods to Help You Lose
- The Truth About Your Poop
- Vinegar May Aid in Fat Loss
- Swine Flu: What Are Symptoms of Swine Flu?
- The Winners for Best Sunscreens Are...



